Not a member? Sign Up

Reasons for Joining

    Address your challenges through knowledge sharing with peers from our global network of specialists.

    Benchmark your business initiatives with the who's who in the field.

    Hear from industry pioneers how to maximize ROI in today's challenging economy.

    And best of all It's FREE!
Sign in using your existing
Pharma IQ account
Username or Email:

Sign Up    |  Already a member? Sign In
Pharma IQ

Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market

Contributor:  Pharma IQ News
Posted:  02/07/2012  12:00:00 AM EST  |  0

Rate this Article: (Be the First!)

Tags:   disposable bioreactors | Contract Manufacturing Organization | CMOs | CMO | upstream bioprocessing | upstream process | disposables | disposable manufacturing

Upstream process is vital in the manufacturing of biopharmaceuticals to have control over growth conditions and nutrients which eventually reflects in an increased overall yield. GBI Research analysis shows that the total upstream market was calculated at $5.4 billion in 2009. The market is expected to grow at a CAGR of 11% for the period 2009-2016, and is expected to reach $11.7 billion by 2016. Advancement in cell culture technologies, innovation in the transgenic production system and the rising demand for biologics is expected to drive the upstream process market.

Upstream Processing in Biopharmaceuticals, Upstream Process  Market Forecast,($bn), 2009-2016
Source: GBI Research
 
Increased Outsourcing to CMO will Steadily Drive CMO Market Growth in Future
Outsourcing to Contract Manufacturing Organization (CMOs) is one of the most significant trends in the healthcare industry, especially in the biopharmaceuticals market. CMOs will be used for most of the processes in the healthcare industry several players from emerging countries are entering the market. Companies from the US and Europe are opening up operations in emerging countries such as India, Korea, China and Singapore. Outsourcing to the CMO is a good option for the big biotechnology companies that want to focus on core competency. Similarly companies lacking the manufacturing infrastructure and technical expertise are outsourcing to the CMO.
 
GBI Research analysis shows that the CMO market for upstream processing was $1.2 billion in 2009 and is expected to grow at a CAGR of 14% to reach at a value of $2.8bn in 2016. The major factor driving the CMO market is the increase in the trend of outsourcing of biopharmaceutical manufacturing to the CMO.

Upstream Processing in Biopharmaceuticals, CMO Upstream Market Forecast,($bn), 2009-2016
Source: GBI Research

Culture Media and Regent Market for Upstream Processing will Experience a Huge Growth in Future

GBI Research analysis shows that the total culture media and reagent market used in upstream processing has been calculated at $1.36 billion for 2009. The market is expected to grow at a CAGR of 11% for the period of 2009-2016, and is expected to reach $2.8 billion by 2016.
Cell culture and reagent is a consolidated market. More than 85%-90% of production of cell culture media, sera, and reagent used in the upstream processing are dominated by a few companies such as Life Technologies and Sigma Aldrich. Increasing interest of emerging countries in the production of biopharmaceutical drugs; patent expiry of some major dugs; and regulatory acceptances to the biosimilars is expected to drive the market in future.

About This Report

GBI Research's report, “Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market”, provides the key to market data on overall upstream process, Contract Manufacturing Organization (CMO) market for upstream processing, and the cell culture and reagent market. Market. The report also analyzes the strengths, weaknesses, opportunities, and threats for the key players in the CMO and cell culture and regent market. The report also discusses the key market drivers and restraints for the upstream processing, outsourcing to CMO and cell culture and reagent market. The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts to provide a comprehensive view of the upstream processing in biopharmaceuticals.
 
To purchase this report go to http://b2b.pharma-iq.com/event.cfm?eventID=229
Have Your Say
Rate this feature and give us your feedback in the comments section below


Pharma IQ News Contributor:   Pharma IQ News

* = required.

Not a member yet? Sign up
User Name:
Password:
You Should Check Out:

Be the first to leave a comment
Sign in or Sign up to post a comment

Advertisement

Events of Interest
Download Brochure

Please complete the information below to complete your download.

Please note: That all fields marked with an asterisk (*) are required.

First Name *
Last Name *
Job Title *
Company Name *
Email Address *
Telephone *
Country *
Where did you hear about us? *

I would like to receive information about sponsorship and exhibition opportunities

Yes, sign me up for the FREE Pharma IQ e-newsletter, including information on FREE Podcasts, Webinars, event discounts and online learning opportunities.

You Might Also Like

Advertisement

Recent Activity